دورية أكاديمية
أعرض في EDS

Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment.

التفاصيل البيبلوغرافية
العنوان: Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment.
المؤلفون: Raguz J; Hookipa Pharma Inc, New York, NY, USA., Pinto C; Hookipa Pharma Inc, New York, NY, USA., Pölzlbauer T; Hookipa Pharma Inc, New York, NY, USA., Habbeddine M; Hookipa Pharma Inc, New York, NY, USA., Rosskopf S; Hookipa Pharma Inc, New York, NY, USA., Strauß J; Hookipa Pharma Inc, New York, NY, USA., Just V; Hookipa Pharma Inc, New York, NY, USA., Schmidt S; Hookipa Pharma Inc, New York, NY, USA., Bidet Huang K; Hookipa Pharma Inc, New York, NY, USA., Stemeseder F; Hookipa Pharma Inc, New York, NY, USA., Schippers T; Hookipa Pharma Inc, New York, NY, USA., Stewart E; Vienna BioCenter Core Facilities GmbH (VBCF), Vienna, Austria., Jez J; Vienna BioCenter Core Facilities GmbH (VBCF), Vienna, Austria., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Orlinger KK; Hookipa Pharma Inc, New York, NY, USA., Lauterbach H; Hookipa Pharma Inc, New York, NY, USA Henning.Lauterbach@hookipapharma.com.
المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Apr 17; Vol. 12 (4). Date of Electronic Publication: 2024 Apr 17.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2020- : London, United Kingdom : BMJ Publishing Group Ltd.
Original Publication: London : BioMed Central, 2013-
مواضيع طبية MeSH: Papillomavirus Vaccines* , Arenavirus*/metabolism , Papillomavirus Infections* , Neoplasms*/therapy, Humans ; Mice ; Animals ; CD8-Positive T-Lymphocytes ; Papillomavirus E7 Proteins ; Disease Models, Animal ; Immunosuppression Therapy ; Tumor Microenvironment
مستخلص: Background: Engineered arenavirus vectors have recently been developed to leverage the body's immune system in the fight against chronic viral infections and cancer. Vectors based on Pichinde virus (artPICV) and lymphocytic choriomeningitis virus (artLCMV) encoding a non-oncogenic fusion protein of human papillomavirus (HPV)16 E6 and E7 are currently being tested in patients with HPV16+ cancer, showing a favorable safety and tolerability profile and unprecedented expansion of tumor-specific CD8 + T cells. Although the strong antigen-specific immune response elicited by artLCMV vectors has been demonstrated in several preclinical models, PICV-based vectors are much less characterized.
Methods: To advance our understanding of the immunobiology of these two vectors, we analyzed and compared their individual properties in preclinical in vivo and in vitro systems. Immunogenicity and antitumor effect of intratumoral or intravenous administration of both vectors, as well as combination with NKG2A blockade, were evaluated in naïve or TC-1 mouse tumor models. Flow cytometry, Nanostring, and histology analysis were performed to characterize the tumor microenvironment (TME) and T-cell infiltrate following treatment.
Results: Despite being phylogenetically distant, both vectors shared many properties, including preferential infection and activation of professional antigen-presenting cells, and induction of potent tumor-specific CD8 + T-cell responses. Systemic as well as localized treatment induced a proinflammatory shift in the TME, promoting the infiltration of inducible T cell costimulator (ICOS) + CD8 + T cells capable of mediating tumor regression and prolonging survival in a TC-1 mouse tumor model. Still, there was evidence of immunosuppression built-up over time, and increased expression of H2-T23 (ligand for NKG2A T cell inhibitory receptor) following treatment was identified as a potential contributing factor. NKG2A blockade improved the antitumor efficacy of artARENA vectors, suggesting a promising new combination approach. This demonstrates how detailed characterization of arenavirus vector-induced immune responses and TME modulation can inform novel combination therapies.
Conclusions: The artARENA platform represents a strong therapeutic vaccine approach for the treatment of cancer. The induced antitumor immune response builds the backbone for novel combination therapies, which warrant further investigation.
Competing Interests: Competing interests: JR, CP, TP, SR, JS, VJ, SS, KBH, FS, TS, KKO and HL are employees of Hookipa Pharma and its subsidiary Hookipa Biotech. MH was an employee of Hookipa Pharma and its subsidiary Hookipa Biotech GmbH when this study was conducted. PB, ES and JJ received research funding from Hookipa Pharma.
(© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
References: Nat Rev Immunol. 2010 Aug;10(8):554-67. (PMID: 20616810)
Front Immunol. 2020 Feb 18;11:188. (PMID: 32133000)
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754. (PMID: 29654146)
Nat Rev Dis Primers. 2020 Nov 26;6(1):92. (PMID: 33243986)
Nat Immunol. 2022 Jun;23(6):836-847. (PMID: 35624209)
Oncoimmunology. 2020 Sep 15;9(1):1809960. (PMID: 33457095)
J Immunol. 2002 Jul 15;169(2):693-701. (PMID: 12097371)
Vaccine. 2004 Jan 2;22(3-4):520-7. (PMID: 14670335)
J Exp Med. 2019 Mar 4;216(3):482-500. (PMID: 30755454)
Front Oncol. 2020 Dec 21;10:545385. (PMID: 33425717)
Cancer Discov. 2019 Apr;9(4):476-481. (PMID: 30862723)
N Engl J Med. 2016 Nov 10;375(19):1856-1867. (PMID: 27718784)
Eur J Cancer. 2016 Nov;67:141-151. (PMID: 27669501)
Oncotarget. 2016 Sep 20;7(38):61670-61678. (PMID: 27557510)
Clin Sci (Lond). 2017 Aug 10;131(17):2201-2221. (PMID: 28798073)
Cell. 2018 Dec 13;175(7):1731-1743.e13. (PMID: 30503213)
Nature. 2020 Jul;583(7817):609-614. (PMID: 32581358)
Clin Cancer Res. 2022 Sep 1;28(17):3695-3708. (PMID: 35511938)
J Exp Med. 1998 Nov 16;188(10):1841-8. (PMID: 9815261)
Nat Med. 2010 Mar;16(3):339-45. (PMID: 20139992)
Head Neck. 2016 Jul;38(7):1074-84. (PMID: 26879675)
Front Pharmacol. 2022 Jan 20;12:753387. (PMID: 35126105)
Immunity. 2007 Aug;27(2):281-95. (PMID: 17723218)
Br J Cancer. 2011 Nov 8;105(10):1533-41. (PMID: 22015556)
Front Immunol. 2016 Aug 10;7:304. (PMID: 27559335)
Cancer Immunol Res. 2019 Aug;7(8):1293-1306. (PMID: 31213473)
Front Pharmacol. 2021 Feb 08;11:629266. (PMID: 33628188)
Cell Rep Med. 2021 Mar 03;2(3):100209. (PMID: 33763654)
Front Oncol. 2021 Mar 05;11:596290. (PMID: 33747915)
Papillomavirus Res. 2018 Jun;5:46-58. (PMID: 29277575)
Science. 2008 Nov 14;322(5904):1097-100. (PMID: 19008445)
Vaccine. 2003 Mar 7;21(11-12):1125-36. (PMID: 12559790)
Lancet. 2019 Nov 23;394(10212):1915-1928. (PMID: 31679945)
Clin Cancer Res. 2018 Feb 1;24(3):634-647. (PMID: 29018052)
Nat Commun. 2021 Aug 5;12(1):4734. (PMID: 34354077)
Nat Rev Clin Oncol. 2019 May;16(5):277-278. (PMID: 30824813)
J Immunol. 2020 Aug 15;205(4):1059-1069. (PMID: 32611727)
Front Oncol. 2020 Oct 07;10:578418. (PMID: 33117715)
Trends Immunol. 2003 Apr;24(4):162-4. (PMID: 12697440)
Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):E5290-9. (PMID: 26351680)
Front Oncol. 2021 Oct 14;11:732166. (PMID: 34722273)
Cancer Cell. 2023 Mar 13;41(3):374-403. (PMID: 36917948)
Nat Rev Cancer. 2012 Mar 15;12(4):298-306. (PMID: 22419253)
Nat Rev Clin Oncol. 2022 May;19(5):306-327. (PMID: 35105976)
J Immunol. 2009 Nov 15;183(10):6513-21. (PMID: 19841192)
Lancet. 2019 Jan 12;393(10167):156-167. (PMID: 30509740)
Cell. 2018 Dec 13;175(7):1744-1755.e15. (PMID: 30503208)
Lancet Glob Health. 2020 Feb;8(2):e180-e190. (PMID: 31862245)
Nat Immunol. 2011 Dec 25;13(2):129-35. (PMID: 22197977)
Methods Mol Biol. 2016;1404:351-364. (PMID: 27076310)
Front Immunol. 2013 Oct 08;4:289. (PMID: 24115947)
Nat Rev Immunol. 2022 Dec;22(12):751-764. (PMID: 35418563)
Nat Commun. 2017 May 26;8:15327. (PMID: 28548102)
Immunology. 2018 May;154(1):3-20. (PMID: 29313948)
Nat Rev Immunol. 2006 Dec;6(12):940-52. (PMID: 17124515)
Cancer Res. 1996 Jan 1;56(1):21-6. (PMID: 8548765)
فهرسة مساهمة: Keywords: Drug Therapy, Combination; Head and Neck Cancer; Immunogenicity, Vaccine; Immunotherapy; Tumor Microenvironment
المشرفين على المادة: 0 (Papillomavirus Vaccines)
0 (Papillomavirus E7 Proteins)
تواريخ الأحداث: Date Created: 20240417 Date Completed: 20240419 Latest Revision: 20240426
رمز التحديث: 20240426
مُعرف محوري في PubMed: PMC11029282
DOI: 10.1136/jitc-2023-008286
PMID: 38631709
قاعدة البيانات: MEDLINE
الوصف
تدمد:2051-1426
DOI:10.1136/jitc-2023-008286